Sarcopenia is a progressive loss of skeletal muscle mass, strength, and physical function that accelerates with age and raises the risk of falls, fractures, disability, and death. The term was coined in 1989 by Irwin Rosenberg, who combined the Greek words for “flesh” and “loss,” but the medical definition has changed considerably since then, shifting from a focus on shrinking muscles to an emphasis on declining muscle strength as the defining feature.1PubMed Central. A short history of sarcopenia and frailty and their impact on advanced chronic liver disease That shift matters for how the condition is screened, diagnosed, and treated.
From Muscle Size to Muscle Strength
Early definitions of sarcopenia centered on how much muscle mass a person had lost compared with a young, healthy reference group. If your lean mass fell below a certain threshold, you qualified. The problem was that muscle mass alone turned out to be a poor predictor of the outcomes people actually care about: falling, losing independence, or dying prematurely. Two people with the same amount of muscle on a scan could have very different strength and mobility levels. Research through the 2000s and 2010s made clear that what your muscles can do matters more than how big they look on an image.
The most widely used current framework comes from the European Working Group on Sarcopenia in Older People, which published updated consensus criteria (EWGSOP2) in 2018. Under those criteria, low muscle strength is the primary indicator. If someone has reduced strength, sarcopenia is considered “probable.” The diagnosis is “confirmed” when imaging or another test also shows low muscle quantity or quality. And when all three elements are present, including poor physical performance, the condition is graded as “severe.”2PubMed Central. Sarcopenia: revised European consensus on definition and diagnosis This three-tier system gives clinicians a way to stage severity rather than treating sarcopenia as a simple yes-or-no label.
Other expert groups have published their own definitions. The Asian Working Group for Sarcopenia (AWGS) updated its criteria in 2019 with population-specific cut-off values reflecting body-size differences. In 2020, the Sarcopenia Definitions and Outcomes Consortium (SDOC) in the United States proposed criteria focused specifically on grip strength and walking speed, chosen because of their ability to predict falls, fractures, and death.3PubMed Central. Putative Cut-Points in Sarcopenia Components and Incident Adverse Health Outcomes: An SDOC Analysis A scoping review of these three definitions noted that while all share the broad concept of muscle decline, data on how well each predicts actual health outcomes are still uneven, particularly for the SDOC and AWGS criteria.4PubMed Central. Predictive validity of current sarcopenia definitions (EWGSOP2, SDOC, and AWGS2) for clinical outcomes: A scoping review
This variety of definitions creates a practical headache. A large multinational European study that applied twelve different sarcopenia definitions to the same group of older adults found prevalence rates that varied wildly depending on which criteria were used.5PubMed Central. Comparing Prevalence of Sarcopenia Using Twelve Sarcopenia Definitions in A Large Multinational European Population of Community-Dwelling Older Adults In other words, whether a given person “has” sarcopenia can depend on which guideline a clinician follows. The field is working toward international consensus, but it is not there yet.
How Sarcopenia Is Assessed in a Clinical Setting
The diagnostic process typically starts with a quick screening step, often a simple questionnaire called the SARC-F that asks about difficulty with activities like lifting a shopping bag, walking across a room, or getting out of a chair. If the screening flags a potential problem, the next step is measuring muscle strength. The two most common methods are a handheld grip-strength dynamometer and the five-times chair-stand test, in which you stand up and sit down five times as fast as you can.
Grip strength is the more established of the two and generally performs better at identifying sarcopenia in community-dwelling older adults.6PubMed. Prevalence and Diagnostic Agreement of Sarcopenia Based on Handgrip Strength and 5-Time Chair-Stand Test Among Chinese Community-Dwelling Older Adults But they are not interchangeable tests. A Norwegian study following several thousand older adults found that grip strength and chair-stand performance each identified different people as being at risk, and both independently predicted death. The researchers recommended measuring both rather than treating one as a substitute for the other.7PubMed Central. Comparing associations of handgrip strength and chair stand performance with all-cause mortality-implications for defining probable sarcopenia: the Tromsø Study 2015-2020 This makes sense when you think about it: grip strength tests the upper body and the chair stand tests the lower body, so they capture different aspects of what muscles can do.
If the strength test is low, most guidelines then call for measuring muscle mass to confirm the diagnosis. The reference standard is dual-energy X-ray absorptiometry, or DXA, which gives a reliable picture of how much lean tissue is in the arms and legs. Bioelectrical impedance analysis (BIA) is cheaper and more portable, but it consistently overestimates muscle mass compared with DXA. One study found BIA overestimated appendicular skeletal muscle mass by roughly 2 kg on average.8PubMed Central. Comparison between Dual-Energy X-ray Absorptiometry and Bioelectrical Impedance Analyses for Accuracy in Measuring Whole Body Muscle Mass and Appendicular Skeletal Muscle Mass That gap can push someone’s reading above the sarcopenia threshold when a DXA scan would have put them below it. Correction equations can shrink that discrepancy substantially.9PubMed Central. Diagnosis of sarcopenia by evaluating skeletal muscle mass by adjusted bioimpedance analysis validated with dual‐energy X‐ray absorptiometry In research settings, CT and MRI scans also appear, and advanced MRI sequences can offer information about muscle quality beyond just size, though these remain expensive and impractical for routine screening.10PubMed Central. Established paths and new avenues: a review of the main radiological techniques for investigating sarcopenia
Finally, physical performance is measured to determine severity. The usual tests are gait speed over a short distance (often four meters) or the Short Physical Performance Battery, which combines walking speed, balance, and chair stands into a single score. Poor performance on these tests pushes the classification from “confirmed” to “severe” sarcopenia under the EWGSOP2 framework.11PubMed Central. Sarcopenia: revised European consensus on definition and diagnosis
Related Conditions That Are Not Quite Sarcopenia
Several overlapping terms create confusion. Dynapenia refers specifically to age-related loss of muscle strength without necessarily losing muscle mass. Some researchers argued as early as 2008 that strength loss and mass loss should be treated as separate problems, because the mechanisms behind each do not fully overlap: you can lose strength through changes in the nervous system and in how muscle fibers contract, even before measurable muscle mass shrinks.12PubMed. Sarcopenia =/= dynapenia Under the EWGSOP2 system, a person with low strength but normal muscle mass would be classified as having “probable sarcopenia,” not dynapenia per se, but the distinction still matters in research contexts.
Pre-sarcopenia describes the opposite pattern: someone whose scans show reduced muscle mass but whose strength and physical function are still normal. A Japanese study mapped out the progression and found that pre-sarcopenia (low mass, normal function), sarcopenia (low mass and low function), and dynapenia (low function, normal mass) each carried different implications for mobility impairment.13PubMed Central. Association of sarcopenia, pre-sarcopenia, and dynapenia with the onset and progression of locomotive syndrome in Japanese older adults: a cross-sectional study
Sarcopenic obesity is another important overlap. This is the combination of sarcopenia with excess body fat, and it can be especially insidious because a person’s body weight may look normal or even high while the muscle underneath is wasting away. A recent Asia-Oceania consensus defined sarcopenic obesity through a three-step algorithm that screens for both obesity and sarcopenia criteria, then confirms each with imaging and strength tests.14PubMed. The Asia-Oceania consensus: Definitions and diagnostic criteria for sarcopenic obesity This is one reason why body weight or BMI alone is a misleading indicator of muscle health in older adults.
Why Muscles Weaken and Shrink With Age
Sarcopenia does not have a single cause. Several biological processes converge, and they feed on each other. One key driver is what researchers call “anabolic resistance”: as people age, their muscles become less responsive to the signals that normally trigger muscle building after eating protein. Younger muscles ramp up protein synthesis efficiently after a meal; older muscles respond sluggishly to the same stimulus.15PubMed. Anabolic resistance of muscle protein synthesis with aging The gap widens in people who are inactive, making sedentary behavior a powerful accelerant.
Equally important are changes in the nervous system. The neuromuscular junction, the point where a nerve signals a muscle fiber to contract, deteriorates with age. Motor units (the nerve cell plus all the muscle fibers it controls) are progressively lost, and the remaining ones try to compensate by “adopting” orphaned fibers, but this remodeling is imperfect. A study that examined neuromuscular impairment at different stages of sarcopenia found elevated markers of junction instability and loss of motor units across all older groups, including older adults who had not yet crossed the threshold into clinical sarcopenia.16PubMed Central. Neuromuscular impairment at different stages of human sarcopenia This suggests that nerve-muscle communication starts degrading well before sarcopenia becomes clinically apparent.17PubMed Central. A neuromuscular perspective of sarcopenia pathogenesis: deciphering the signaling pathways involved
Hormonal declines (testosterone, growth hormone, insulin-like growth factor), chronic low-grade inflammation, and reduced physical activity all pile on. Though sarcopenia is primarily associated with aging, it can also develop in younger people under certain conditions, including cancer, rheumatoid arthritis, prolonged bed rest, and severe malnutrition.
What Sarcopenia Does to Health
The clinical consequences are serious. A systematic review and meta-analysis of 20 studies found that people with sarcopenia had about 60 percent higher odds of falling in cross-sectional analyses, and close to 90 percent higher odds in studies that followed people over time. The same review found roughly 70 to 80 percent higher odds of fractures in sarcopenic individuals.18PubMed Central. Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis Falls rank among the leading causes of chronic disability in older adults, so the sarcopenia-fall connection carries enormous public-health weight.19PubMed Central. A Review on Aging, Sarcopenia, Falls, and Resistance Training in Community-Dwelling Older Adults
Beyond falls, a separate meta-analysis found that sarcopenic individuals had more than triple the odds of dying over the follow-up period compared with non-sarcopenic peers, along with roughly triple the odds of functional decline.20PLoS ONE. Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis Sarcopenia is also linked to longer hospital stays, more post-surgical complications, and higher rates of institutionalization. The SDOC analysis specifically confirmed that older adults with both weak grip strength and slow walking speed were consistently more likely to experience falls, hip fractures, mobility limitation, or death than those with neither deficit.21PubMed Central. Putative Cut-Points in Sarcopenia Components and Incident Adverse Health Outcomes: An SDOC Analysis
Sarcopenia as an Official Disease
For decades, muscle wasting in older adults was treated as an inevitable part of aging rather than a medical condition. That changed in 2016, when sarcopenia received its own code in the International Classification of Diseases (ICD-10-CM code M62.84). This was a significant turning point: having a disease code means clinicians can formally diagnose it, insurers can track it, and pharmaceutical companies have greater incentive to develop drugs targeting the condition.22PubMed Central. Welcome to the ICD‐10 code for sarcopenia In practice, sarcopenia is still underdiagnosed. Many clinicians do not routinely screen for it, and no widely adopted blood test exists to flag it the way cholesterol levels flag cardiovascular risk.
Exercise and Protein Are Still the Foundation
Resistance exercise, meaning any activity that makes muscles work against a load, is the single most effective intervention for sarcopenia. When combined with additional protein, the results are stronger. A meta-analysis of studies in community-dwelling older adults with sarcopenia found that protein supplementation paired with resistance exercise led to significant gains in both muscle mass and strength.23PubMed Central. The effectiveness of protein supplementation combined with resistance exercise programs among community-dwelling older adults with sarcopenia: a systematic review and meta-analysis A systematic review of biomarker-level effects added more detail: resistance training roughly three times per week at moderate-to-high intensity, combined with at least 15 grams of daily protein supplementation, produced favorable shifts in the hormones and inflammatory signals that regulate muscle growth.24PubMed Central. Synergistic Effects of Protein Intake and Exercise on Biomarkers of Sarcopenia: A Systematic Review
The anabolic resistance described earlier is directly relevant here. Because aging muscles do not respond as efficiently to protein, the timing and amount of intake matter. Exercising before eating protein appears to increase how well the muscles use the amino acids they receive.25PubMed. Anabolic resistance of muscle protein synthesis with aging This is why guidelines for older adults generally recommend higher protein intakes spread across multiple meals rather than concentrated in one sitting.
Drugs in the Pipeline
No drug is currently approved specifically for sarcopenia, but several are in late-phase clinical trials. The most-watched categories include myostatin-neutralizing antibodies like bimagrumab and LY2495655 (myostatin is a protein that limits muscle growth, so blocking it should allow muscles to get bigger), and selective androgen receptor modulators (SARMs) like enobosarm, which aim to mimic some of testosterone’s muscle-building effects without its broader hormonal side effects. Both drug classes have shown dose-dependent gains in lean mass in trials, with some preliminary functional improvements.26PubMed. Sarcopenia in Aging: Pathogenesis, Diagnosis, and Emerging Therapeutic Frontiers Other approaches target appetite through ghrelin-related compounds (ghrelin is the “hunger hormone”) or aim to protect mitochondria, the energy-producing structures inside muscle cells, from age-related damage.27PubMed. Targeting skeletal muscle wasting: emerging therapeutics and translational challenges The consensus expectation is that future treatment will combine lifestyle changes with drug therapy rather than replacing exercise and nutrition altogether.
Blood Biomarkers on the Horizon
One of the biggest gaps in sarcopenia care is the lack of a simple blood test. Grip dynamometers and DXA scans require dedicated equipment and trained staff, which limits screening in primary care. Researchers have been exploring whether blood-based markers could fill that gap, and one candidate getting sustained attention is C-terminal agrin fragment (CAF). Agrin is a protein that helps stabilize the neuromuscular junction; when the junction degrades, a fragment of agrin is clipped off and released into the bloodstream. Higher levels of this fragment correlate with lower muscle mass and weaker grip strength.
An early study found that roughly 40 percent of sarcopenia patients had CAF levels distinctly elevated above those of age-matched healthy controls, suggesting the existence of an “agrin-dependent” subtype of the condition.28PubMed. Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients Later work confirmed that CAF levels are higher in both sarcopenic and pre-sarcopenic individuals compared with healthy older adults, though the strength of the association varies by sex, appearing stronger in men.29The Journals of Gerontology: Series A. Plasma C-Terminal Agrin Fragment as an Early Biomarker for Sarcopenia: Results From the GenoFit Study A recent meta-analysis supported the overall link between elevated CAF and sarcopenia, including associations with reduced grip strength and muscle mass index, and concluded that CAF could serve as a tool for early detection.30PubMed Central. C‐Terminal Agrin Fragment as a Biomarker for Sarcopenia: A Systematic Review and Meta‐Analysis No blood marker is ready for routine clinical use yet, but CAF represents the most advanced candidate for turning sarcopenia screening into something as straightforward as a blood draw.